Pfizer will be able to deliver 200 million COVID-19 vaccine doses by the end of May
Pfizer will be able to provide the United States with 200 million doses of the COVID-19 vaccine it developed alongside BioNTech by the end of May, CEO Albert Bourla said Tuesday, per Bloomberg. That's two months ahead of the previous July 31 deadline the company had set for itself.
The reason for the apparent fast-tracking is actually a Food and Drug Administration-approved label change, which went into effect Monday, allowing health care workers to extract an additional sixth dose from each vial, so production levels won't necessarily increase. Bourla also said the alteration means Pfizer will be able to deliver 120 million doses to the U.S. by the end of March, 20 million more than promised when the vaccine was initially granted emergency use.
As Bloomberg notes, the expedited timeline comes amid widespread concern about the slower-than-anticipated pace of the vaccine rollout in the U.S., so it's welcome news, though Bourla also suggested things will pick up in the coming weeks, either way. Read more at Bloomberg.
The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Tim is a staff writer at The Week and has contributed to Bedford and Bowery and The New York Transatlantic. He is a graduate of Occidental College and NYU's journalism school. Tim enjoys writing about baseball, Europe, and extinct megafauna. He lives in New York City.
-
Political cartoons for January 11Cartoons Sunday’s political cartoons include green energy, a simple plan, and more
-
The launch of the world’s first weight-loss pillSpeed Read Novo Nordisk and Eli Lilly have been racing to release the first GLP-1 pill
-
Maduro’s capture: two hours that shook the worldTalking Point Evoking memories of the US assault on Panama in 1989, the manoeuvre is being described as the fastest regime change in history
-
Trump HHS slashes advised child vaccinationsSpeed Read In a widely condemned move, the CDC will now recommend that children get vaccinated against 11 communicable diseases, not 17
-
FDA OKs generic abortion pill, riling the rightSpeed Read The drug in question is a generic version of mifepristone, used to carry out two-thirds of US abortions
-
RFK Jr. vaccine panel advises restricting MMRV shotSpeed Read The committee voted to restrict access to a childhood vaccine against chickenpox
-
Texas declares end to measles outbreakSpeed Read The vaccine-preventable disease is still spreading in neighboring states, Mexico and Canada
-
RFK Jr. shuts down mRNA vaccine funding at agencySpeed Read The decision canceled or modified 22 projects, primarily for work on vaccines and therapeutics for respiratory viruses
-
Measles cases surge to 33-year highSpeed Read The infection was declared eliminated from the US in 2000 but has seen a resurgence amid vaccine hesitancy
-
Kennedy's vaccine panel signals skepticism, changeSpeed Read RFK Jr.'s new vaccine advisory board intends to make changes to the decades-old US immunization system
-
Kennedy ousts entire CDC vaccine advisory panelspeed read Health Secretary RFK Jr. is a longtime anti-vaccine activist who has criticized the panel of experts
